{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T05:04:17Z","timestamp":1789535057993,"version":"build-2803163510"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Reliable prognostic biomarkers are needed for IgA nephropathy (IgAN), a common glomerular disease frequently progressing to end-stage renal disease (ESRD). Given bilirubin\u2019s antioxidant and dyslipidemia\u2019s pro-inflammatory roles, we hypothesized that TBIL-lipid ratios would serve as novel composite biomarkers associated with renal outcomes in IgAN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We evaluated four serum bilirubin-lipid ratios (TBIL\/Triglyceride, TBIL\/Cholesterol, TBIL\/HDL, TBIL\/LDL) using Cox regression, restricted cubic spline (RCS), and linear mixed-effects (LME) models in biopsy-proven IgAN patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 1352 patients included in this study, 283 (20.93%) developed composite renal outcome (\u226530% decline in estimated glomerular filtration rate [eGFR] or ESRD). Multivariable Cox analysis showed that all four ratios were independently associated with reduced outcome risk: TBIL\/Triglyceride (HR\u00a0=\u00a00.972, P\u00a0=\u00a00.025), TBIL\/Cholesterol (HR\u00a0=\u00a00.849, P\u00a0=\u00a00.003), TBIL\/HDL (HR\u00a0=\u00a00.970, P\u00a0=\u00a00.030), and TBIL\/LDL (HR\u00a0=\u00a00.926, P\u00a0=\u00a00.004). Although the proportional hazards assumption was violated (all P &amp;lt; 0.05), time-dependent and piecewise Cox models confirmed that the protective effects remained significant in the early phase (\u22643.13 years) but attenuated thereafter. RCS analyses demonstrated linear inverse associations for TBIL\/Triglyceride, TBIL\/Cholesterol, and TBIL\/HDL, whereas TBIL\/LDL exhibited a threshold-saturation pattern. These associations were more pronounced in those with advanced tubulointerstitial lesions (Oxford T1\/T2). In LME models, all four ratios were positively associated with longitudinal eGFR levels (TBIL\/Triglyceride: Estimate = 0.318, P\u00a0=\u00a00.002; TBIL\/Cholesterol: Estimate = 1.242, P\u00a0=\u00a00.004; TBIL\/HDL: Estimate = 0.289, P\u00a0=\u00a00.007; TBIL\/LDL: Estimate = 0.446, P\u00a0=\u00a00.031), with associations remaining stable during follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Higher serum bilirubin-lipid ratios, particularly TBIL\/Cholesterol, were independently associated with lower risk of adverse renal outcomes and better preserved renal function in IgAN patients. These readily available biomarkers may provide additional value for risk stratification in clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1898387","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T04:30:32Z","timestamp":1789533032000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic value of serum total bilirubin-lipid ratios in patients with IgA nephropathy"],"prefix":"10.3389","volume":"17","author":[{"given":"Siwen","family":"Wang","sequence":"first","affiliation":[{"name":"Division of Nephrology, Department of Medicine, West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilin","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Zhou","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingqiu","family":"Dong","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Tang","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxing","family":"Tan","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Qin","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41572-023-00476-9","article-title":"IgA nephropathy","volume":"9","author":"Stamellou","year":"2023","journal-title":"Nat Rev Dis Primer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41581-024-00885-3","article-title":"The pathogenesis of IgA nephropathy and implications for treatment","volume":"21","author":"Cheung","year":"2025","journal-title":"Nat Rev Nephrol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1159\/000317199","article-title":"Oxidative stress in IgA nephropathy","volume":"116","author":"Coppo","year":"2010","journal-title":"Nephron Clin Pract"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2021.01.024","article-title":"IgA nephropathy: core curriculum 2021","volume":"78","author":"Pattrapornpisut","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfq665","article-title":"The incidence of primary glomerulonephritis worldwide: a systematic review of the literature","volume":"26","author":"McGrogan","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.70097","article-title":"Association of serum total bilirubin to cholesterol ratio with progression of chronic kidney disease in patients with type 2 diabetes: a retrospective cohort study","volume":"17","author":"Chen","year":"2025","journal-title":"J Diabetes"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.00549","article-title":"Serum total bilirubin and progression of chronic kidney disease and mortality: a systematic review and meta-analysis","volume":"7","author":"Li","year":"2020","journal-title":"Front Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12944-024-02004-4","article-title":"Lipid parameters, adipose tissue distribution and prognosis prediction in chronic kidney disease patients","volume":"23","author":"Chen","year":"2024","journal-title":"Lipids Health Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcibr2013250","article-title":"Bilirubin, intestinal integrity, the microbiome, and inflammation","volume":"383","author":"V\u00edtek","year":"2020","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20010117","article-title":"Beyond a measure of liver function\u2014bilirubin acts as a potential cardiovascular protector in chronic kidney disease patients","volume":"20","author":"Tsai","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00039.2014","article-title":"Circulating bilirubin and defense against kidney disease and cardiovascular mortality: mechanisms contributing to protection in clinical investigations","volume":"307","author":"Boon","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1080\/13510002.1997.11747098","article-title":"Interactions between bilirubin and reactive oxygen species in liver microsomes and in human neutrophil granulocytes","volume":"3","author":"L\u00e4er","year":"1997","journal-title":"Redox Rep Commun Free Radic Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2023.0067","article-title":"Dyslipidemia in patients with chronic kidney disease: an updated overview","volume":"47","author":"Suh","year":"2023","journal-title":"Diabetes Metab J"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2023.155718","article-title":"Interplay of lipid metabolism and inflammation in podocyte injury","volume":"150","author":"Luo","year":"2024","journal-title":"Metabolism"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2025.2577677","article-title":"Modifying hy\u2019s law and eDISH for the modern idiosyncratic DILI era","volume":"21","author":"Cohen","year":"2025","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-S002","article-title":"2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2021","volume":"44","year":"2021","journal-title":"Diabetes Care"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","article-title":"2020 international society of hypertension global hypertension practice guidelines","volume":"75","author":"Unger","year":"2020","journal-title":"Hypertension"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2188\/jea.JE20130062","article-title":"Is a cutoff of 10% appropriate for the change-in-estimate criterion of confounder identification","volume":"24","author":"Lee","year":"2014","journal-title":"J Epidemiol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-12-156","article-title":"Combining directed acyclic graphs and the change-in-estimate procedure as a novel approach to adjustment-variable selection in epidemiology","volume":"12","author":"Evans","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00265-010-1037-6","article-title":"A brief guide to model selection, multimodel inference and model averaging in behavioural ecology using Akaike\u2019s information criterion","volume":"65","author":"Symonds","year":"2011","journal-title":"Behav Ecol Sociobiol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/srep15482","article-title":"Endogenously elevated bilirubin modulates kidney function and protects from circulating oxidative stress in a rat model of adenine-induced kidney failure","volume":"5","author":"Boon","year":"2015","journal-title":"Sci Rep"},{"key":"B22","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s00011-025-02049-w","article-title":"Bilirubin metabolism and its application in disease prevention: mechanisms and research advances","volume":"74","author":"Zhang","year":"2025","journal-title":"Inflammation Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.60111","article-title":"Lower serum bilirubin is associated with poor renal outcome in IgA nephropathy patients","volume":"18","author":"Jiang","year":"2021","journal-title":"Int J Med Sci"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2009.24.S1.S22","article-title":"The mildly elevated serum bilirubin level is negatively associated with the incidence of end stage renal disease in patients with IgA nephropathy","author":"Chin","year":"2009","journal-title":"J Korean Med Sci"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-015-1096-0","article-title":"Prognostic impact of serum bilirubin level on long-term renal survival in IgA nephropathy","volume":"19","author":"Tanaka","year":"2015","journal-title":"Clin Exp Nephrol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-023-00741-w","article-title":"Kidney lipid dysmetabolism and lipid droplet accumulation in chronic kidney disease","volume":"19","author":"Mitrofanova","year":"2023","journal-title":"Nat Rev Nephrol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.56434\/j.arch.esp.urol.20247705.73","article-title":"Correlation of serum bilirubin with clinical and pathological characteristics of patients with IgA nephropathy","volume":"77","author":"Xu","year":"2024","journal-title":"Arch Esp Urol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2014.29.S2.S155","article-title":"Effect of bilirubin on triglyceride synthesis in streptozotocin-induced diabetic nephropathy","volume":"29","author":"Xu","year":"2014","journal-title":"J Korean Med Sci"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-19-0394-6_9","article-title":"Cholesterol metabolism in chronic kidney disease: physiology, pathologic mechanisms, and treatment","volume":"1372","author":"Pan","year":"2022","journal-title":"Adv Exp Med Biol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000184250.37607.da","article-title":"Pathways of renal fibrosis and modulation of matrix turnover in experimental hypercholesterolemia","volume":"46","author":"Chade","year":"2005","journal-title":"Hypertension"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2022.155377","article-title":"ABCA1 deficiency-mediated glomerular cholesterol accumulation exacerbates glomerular endothelial injury and dysfunction in diabetic kidney disease","volume":"139","author":"Zhang","year":"2023","journal-title":"Metabolism"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M116.730564","article-title":"Exendin-4 ameliorates lipotoxicity-induced glomerular endothelial cell injury by improving ABC transporter A1-mediated cholesterol efflux in diabetic apoE knockout mice*","volume":"291","author":"Yin","year":"2016","journal-title":"J Biol Chem"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1089\/dna.2023.0410","article-title":"m6A RNA methylation and implications for hepatic lipid metabolism","volume":"43","author":"Ming","year":"2024","journal-title":"DNA Cell Biol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/nrm4074","article-title":"Transcriptional regulation of hepatic lipogenesis","volume":"16","author":"Wang","year":"2015","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10184236","article-title":"Hypertriglyceridemia is associated with more severe histological glomerulosclerosis in IgA nephropathy","volume":"10","author":"Choi","year":"2021","journal-title":"J Clin Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-021-02844-4","article-title":"Hyperuricemia and hypertriglyceridemia indicate tubular atrophy\/interstitial fibrosis in patients with IgA nephropathy and membranous nephropathy","volume":"53","author":"Liu","year":"2021","journal-title":"Int Urol Nephrol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1037773","article-title":"Prognostic value of low-density lipoprotein cholesterol in IgA nephropathy and establishment of nomogram model","volume":"14","author":"Tian","year":"2023","journal-title":"Front Endocrinol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfz103.SP332","article-title":"LDL-cholesterol level is associated with downregulation of klotho expression in patients with IgA nephropathy","volume":"34","author":"Doi","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-008-1127-4","article-title":"Effects of different LDL particles on inflammatory molecules in human mesangial cells","volume":"51","author":"Santini","year":"2008","journal-title":"Diabetologia"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-018-4104-2","article-title":"Kidney as modulator and target of \u201cgood\/bad\u201d HDL","volume":"34","author":"Zhong","year":"2019","journal-title":"Pediatr Nephrol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3390\/cells10040764","article-title":"High-density lipoproteins and the kidney","volume":"10","author":"Strazzella","year":"2021","journal-title":"Cells"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.05.020","article-title":"Kidney function is associated with an altered protein composition of high-density lipoprotein","volume":"92","author":"Rubinow","year":"2017","journal-title":"Kidney Int"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2015.05.009","article-title":"Residual cardiovascular risk in chronic kidney disease: role of high-density lipoprotein","volume":"46","author":"Kon","year":"2015","journal-title":"Arch Med Res"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2010.36","article-title":"HDL metabolism and activity in chronic kidney disease","volume":"6","author":"Vaziri","year":"2010","journal-title":"Nat Rev Nephrol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.6121","article-title":"On representing the prognostic value of continuous gene expression biomarkers with the restricted mean survival curve","volume":"6","author":"Eng","year":"2015","journal-title":"Oncotarget"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/1302811","article-title":"Methods to analyze time-to-event data: the cox regression analysis","volume":"2021","author":"Abd ElHafeez","year":"2021","journal-title":"Oxid Med Cell Longev"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/sim.2929","article-title":"Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond","volume":"27","author":"Pencina","year":"2008","journal-title":"Stat Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2009.184","article-title":"An update on the lipid nephrotoxicity hypothesis","volume":"5","author":"Ruan","year":"2009","journal-title":"Nat Rev Nephrol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.2741\/E329","article-title":"Optimal cut-off values for tumor markers in cerebrospinal fluid with ROC curve analysis","volume":"3","author":"Shi","year":"2011","journal-title":"Front Biosci-Elite"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.spasta.2020.100424","article-title":"Understanding the effects of dichotomization of continuous outcomes on geostatistical inference","volume":"42","author":"Kyomuhangi","year":"2021","journal-title":"Spat Stat"},{"key":"B51","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s00467-015-3169-4","article-title":"Tubular atrophy in the pathogenesis of chronic kidney disease progression","volume":"31","author":"Schelling","year":"2016","journal-title":"Pediatr Nephrol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1111\/1440-1681.13556","article-title":"Renal lipotoxicity: insights from experimental models","volume":"48","author":"Castro","year":"2021","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.5368","article-title":"Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial","volume":"327","author":"Lv","year":"2022","journal-title":"JAMA"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2013.210","article-title":"Individuals of pacific asian origin with IgA nephropathy have an increased risk of progression to end-stage renal disease","volume":"84","author":"Barbour","year":"2013","journal-title":"Kidney Int"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1898387\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T04:30:36Z","timestamp":1789533036000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1898387\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":54,"alternative-id":["10.3389\/fendo.2026.1898387"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1898387","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"article-number":"1898387"}}